Evidence map›Paper›PMID 33796267›Full record

ArticleTherapeutic advances in psychopharmacology2021

Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital.

Jeroen Govaerts, Julie Boeyckens, Astrid Lammens, Annelies Gilis, Filip Bouckaert, Marc De Hert, Jan De Lepeleire, Brendon Stubbs, Franciska Desplenter

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Complex Psychotropic Polypharmacy in Soweto-based community psychiatry clinics.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jeroen GovaertsUniversity Psychiatric Center Katholieke Universiteit (KU) Leuven, Leuvensesteenweg 517, Kortenberg, 3070, Belgium.ORCID https://orcid.org/0000-0001-8168-6953
Julie BoeyckensDepartment of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Astrid LammensDepartment of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Annelies GilisDepartment of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Filip BouckaertUniversity Psychiatric Center KU Leuven, Kortenberg, Belgium.
Marc De HertUniversity Psychiatric Center KU Leuven, Kortenberg, Belgium.
Jan De LepeleireUniversity Psychiatric Center KU Leuven, Kortenberg, Belgium.
Brendon StubbsPhysiotherapy Department, South London and Maudsley NHS Foundation Trust, London, United Kingdom. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Franciska DesplenterUniversity Psychiatric Center KU Leuven, Kortenberg, Belgium.
KU Leuven · BEKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis cross-sectional pharmacoepidemiologic study examined the prevalence of polypharmacy and psychotropic polypharmacy among inpatients in a tertiary psychiatric hospital in Belgium.

methodsCurrent prescriptions of all inpatients suffering from mental disorders were extracted from the hospital Computerized Physician Order Entry. Two methods were used to examine definitive polypharmacy (defined as the concomitant use of at least five medicines): number of medicines per active component and per prescription. Psychotropic polypharmacy was defined as the concomitant use of at least two psychotropic medicines, based on the first counting, i.e., per active component.

resultsIn 292 included patients, the prevalence of definitive polypharmacy was 65.8%, with a mean number of 6.8 ± 4.2 medicines per patient. The most prevalent medicines were related to the central nervous system (55.7%), followed by medicines related to the gastro-intestinal (17.6%) and cardiovascular (9.4%) systems. A prevalence of psychotropic polypharmacy of 78.1% was observed, with a mean of 3.0 ± 1.7 psychotropic medicines per patient. Psychotropic polypharmacy was classified in same-class (71.5%), multi-class (82.5%), augmentation (20.6%), and adjuvant (35.5%) polypharmacy.

conclusionThese findings are consistent with previous reports of highly prevalent polypharmacy in patients with mental disorders. Although, in some cases, polypharmacy can be an important part of good clinical practice, the high prevalence of both polypharmacy and psychotropic polypharmacy emphasizes that attention must be paid to the potentially associated risks. Consensus on the definition and method of determination of polypharmacy is needed to support further research.

Indexed as

pharmacoepidemiologypolypharmacypsychiatrypsychotropic polypharmacy

Identifiers

PMID33796267
PMCPMC7985946
OpenAlexW3138019345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.